PeopleBio피플바이오
304840 · KOSDAQ · ₩304840 · 피플바이오
₩561 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩2.9B | ₩3.7B | ₩4.5B | ₩4.4B | ₩577M |
| Cost of sales | ₩3.3B | ₩2.4B | ₩3B | ₩3.1B | ₩1.3B |
| Gross profit | −₩464M | ₩1.4B | ₩1.4B | ₩1.4B | −₩771M |
| Operating income | −₩8.4B | −₩12B | −₩15B | −₩12B | −₩7.2B |
| Net income | −₩17B | −₩12B | −₩17B | −₩700M | −₩4.9B |
| Net income to shareholders | −₩16B | −₩11B | −₩16B | −₩14B | −₩4.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩45B | ₩27B | ₩28B | ₩42B | ₩51B |
| Current assets | ₩4.4B | ₩17B | ₩15B | ₩29B | ₩40B |
| Cash and equivalents | ₩80M | ₩1.3B | ₩691M | ₩14B | ₩39B |
| Total liabilities | ₩16B | ₩19B | ₩7.9B | ₩36B | ₩32B |
| Current liabilities | ₩14B | ₩17B | ₩3.5B | ₩33B | ₩29B |
| Borrowings | ₩7.4B | ₩8.5B | ₩1.3B | ₩15B | ₩13B |
| Total equity | ₩29B | ₩7.6B | ₩20B | ₩5.9B | ₩19B |
| Shareholders' equity | ₩29B | ₩8.4B | ₩19B | ₩4.1B | ₩17B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.2B | −₩11B | −₩16B | −₩14B | −₩6.8B |
| Capital spending | ₩214M | ₩79M | ₩719M | ₩1.3B | ₩1.4B |
| Free cash flow | −₩5.4B | −₩11B | −₩17B | −₩15B | −₩8.2B |
Consolidated where available. Amounts in won.
Also known as: PeopleBio / 피플바이오 / 304840 / KRX:304840
Source: KRX statistical information